T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Experimental Hematology

• Publication date

  2005-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EXPHEM.2005.01.007PMID 15781336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Infusions of T Cells Armed with Anti-CD3 x Anti-Her2/neu Bispecific Antibody Modulate In Vivo Patient Immune Responses in Phase I Clinical Trials for Breast and Hormone Refractory Prostate Cancers.

  2004cited by this paper
• Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.

  2004cited by this paper
• In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

  2003cited by this paper
• The mechanisms of action of rituximab in the elimination of tumor cells.

  2003cited by this paper
• Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1

  2003cited by this paper
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

  2003cited by this paper
• Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.

  2003cited by this paper
• Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

  2003cited by this paper
• Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody

  2002cited by this paper
• Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies

  2001cited by this paper
• Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.

  2001cited by this paper
• Use of Anti-CD3 × Anti-HER2/neu Bispecific Antibody for Redirecting Cytotoxicity of Activated T Cells Toward HER2/neu+ Tumors

  2001cited by this paper
• Cell surface complement inhibitors cd55 and cd59 may mediate chronic lymphocytic leukemia (cll) resistance to rituximab therapy

  2000cited by this paper
• A UK multicentre phase II study of rituximab (chimaeric anti‐CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response

  2000cited by this paper
• Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.

  2000cited by this paper
• Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.

  2000cited by this paper
• Cytokine therapy for cancer.

  2000cited by this paper
• Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

  1999cited by this paper
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

  1998cited by this paper
• Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.

  1995cited by this paper
• Bispecific monoclonal antibody therapy of B-cell malignancy.

  1995cited by this paper
• PRECLINICAL STUDIES FOR ADOPTIVE IMMUNOTHERAPY IN BONE MARROW TRANSPLANTATION: GENERATION OF ANTI‐CD3 ACTIVATED CYTOTOXIC T CELLS FROM NORMAL DONORS AND AUTOLOGOUS BONE MARROW TRANSPLANT CANDIDATES

  1993cited by this paper
• Negative modulation of Epstein-Barr virus episomes by a human B-cell growth factor

  1989cited by this paper

• Generation of IL‐2‐Fc‐antibody conjugates by click chemistry

  2023cites this paper
• Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.

  2023cites this paper
• Review on Monoclonal Antibodies (mAbs) as a Therapeutic Approach for Type 1 Diabetes.

  2023cites this paper
• Rapid, site-specific labeling of “off-the-shelf” and native serum autoantibodies with T cell–redirecting domains

  2022cites this paper
• Chemical and Enzymatic Methods for Post-Translational Protein–Protein Conjugation

  2022cites this paper
• Transient B-cell depletion and regulatory T-cells mediation in combination with adenovirus mediated IGF-1 prevents and reverses autoimmune diabetes in NOD mice

  2022cites this paper
• T‐cell surface generation of dual bivalent, bispecific T‐cell engaging, RNA duplex cross‐linked antibodies (dbBiTERs) for re‐directed tumor cell lysis

  2021cites this paper
• Monoclonal Antibodies for Cancer Immunotherapy

  2020cites this paper
• Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines

  2020cites this paper
• The Epigenetic Regulation of Blinatumomab Gene Expression: Tumor Cell-dependent T cell Response against Lymphoma Cells and Cytotoxic Activity

  2019cites this paper
• A plug-and-play approach for the de novo generation of dually functionalised bispecifics.

  2019cites this paper
• Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy

  2019cites this paper
• Immune T cells can transfer and boost anti-breast cancer immunity

  2018cites this paper
• Bispecific antibodies: design, therapy, perspectives

  2018cites this paper
• Redirecting T cells to hematological malignancies with bispecific antibodies.

  2018cites this paper
• Specific Adoptive T-Cell Therapy for Viral and Fungal Infections

  2018cites this paper
• IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells

  2018cites this paper
• T cell engaging bispecific antibody (T‐BsAb): From technology to therapeutics

  2017cites this paper
• Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.

  2016cites this paper
• Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab

  2016cites this paper
• Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial

  2015cites this paper
• Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity

  2015cites this paper
• Activated T cells armed with bispecific antibodies kill tumor targets

  2015cites this paper
• The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.

  2015cites this paper
• Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cells.

  2015cites this paper
• Monoclonal Antibodies for Cancer Immunotherapy

  2015cites this paper
• Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells

  2014cites this paper
• Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study

  2014cites this paper
• Ipilimumab augments antitumor activity of bispecific antibody-armed T cells

  2014cites this paper
• Multi-Specific Antibodies for Cancer Immunotherapy

  2014cites this paper
• 11. Bispecific Antibodies

  2014cites this paper
• Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells

  2013cites this paper
• Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies

  2013cites this paper
• CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.

  2013cites this paper
• New strategies for allogeneic hematopoietic stem cell transplantation with umbilical cord

  2013cites this paper
• Anti‐CD3 × anti‐GD2 bispecific antibody redirects T‐cell cytolytic activity to neuroblastoma targets

  2012cites this paper
• Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.

  2012cites this paper
• Pediatr Blood Cancer 2012 ; 59 : 1198 – 1205 Anti-CD 3 T Anti-GD 2 Bispecific Antibody Redirects T-Cell Cytolytic Activity to Neuroblastoma Targets

  2012cites this paper
• Activated T cells from umbilical cord blood armed with anti‐CD3 × anti‐CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants

  2012cites this paper
• In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells

  2011influential citation
• Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment

  2011cites this paper
• Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia

  2011cites this paper
• Agents et méthodes de traitement de maladies qui sont corrélées à une expression de bcma

  2011cites this paper
• Bispecific Antibodies for Arming Activated T Cells and Other Effector Cells for Tumor Therapy

  2011cites this paper
• Administration of adenovirus encoding anti-CD20 antibody gene induces B-cell deletion and alleviates lupus in the BWF1 mouse model.

  2011cites this paper
• Targeting T Cells with Bispecific Antibodies for Cancer Therapy

  2011cites this paper
• SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.

  2010cites this paper
• Bispecific Antibodies for Cancer Immunotherapy

  2010cites this paper
• Rationale and development of multispecific antibody drugs

  2010cites this paper
• Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms

  2010cites this paper
• Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

  2010cites this paper
• Antibody-based cancer therapy

  2008cites this paper
• Monoclonal antibodies in the treatment of lymphoid malignancies.

  2008cites this paper
• Tissue engineering and stem cell therapy for myocardial repair.

  2007cites this paper
• Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for graft-versus-host disease in allogeneic antitumor cell therapy

  2007cites this paper
• Recombinant bispecific antibodies for cellular cancer immunotherapy.

  2007cites this paper
• CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma

  2007cites this paper
• Antibody Targeting of Stem Cells to Infarcted Myocardium

  2007cites this paper
• Entwicklung von spezifischen Immuntherapien in der Dermato-Onkologie

  2006cites this paper
• Anti-CD3 × Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an Animal Model

  2006cites this paper
• The new face of bispecific antibodies: targeting cancer and much more.

  2006cites this paper
• Recombinant bispecific antibodies for cancer therapy

  2005cites this paper
• Anti-CD 3 Anti-Epidermal Growth Factor Receptor ( EGFR ) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an AnimalModel

  2005cites this paper